Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 3/20 | 0.34 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | ICMT | O60725 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5357737 | 0.83 | P2RX7 (0.38) | ALDH1A1OPRM1OPRL1 | |
| SCHEMBL5369345 | 0.82 | SLC6A2 (0.36) | SLC6A4SLC6A3SLC6A2OPRM1OPRL1 | |
| SCHEMBL5365666 | 0.78 | MEN1 (0.45) | CYP2C19ALDH1A1OPRD1OPRK1 | |
| SCHEMBL5358531 | 0.74 | SLC6A4 (0.41) | SLC6A4SLC6A3SLC6A2ALDH1A1TACR1 | |
| SCHEMBL14417007 | 0.74 | SLC6A4 (0.47) | SLC6A4SLC6A3SLC6A2CYP2C19ALDH1A1 | |
| SCHEMBL5358527 | 0.73 | SLC6A4 (0.42) | SLC6A4SLC6A3SLC6A2CYP2C19ALDH1A1 | |
| SCHEMBL5372808 | 0.71 | SIGMAR1 (0.56) | ALDH1A1 | |
| SCHEMBL14417006 | 0.71 | SLC6A4 (0.41) | SLC6A4SLC6A3SLC6A2CYP2C19ALDH1A1 | |
| SCHEMBL5366545 | 0.71 | CCR3 (0.47) | ALDH1A1OPRM1OPRL1OPRK1 | |
| SCHEMBL5369330 | 0.69 | SLC6A9 (0.38) | SLC6A4SLC6A3SLC6A2OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225331-A1 | 4,4-Disubstituted piperidines, and methods of use thereof | SEPRACOR INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7217823-B2 | 4,4-Disubstituted piperidines, and methods of use thereof | SEPRACOR INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20040142974-A1 | 4,4-disubstituted piperidines, and methods of use thereof | HOEMANN MICHAEL Z (US) | 2004-07-22 | — | — | US | disclosed |
| US-6656953-B2 | Ligands for receptors such as dopamine, serotonin, or norepinephrine transporters; broad uses claimed, such as pain reliever and antidepressant | SEPRACOR INC. | 2003-12-02 | — | — | US | disclosed |
| US-20020177607-A1 | 4,4-Disubstitued piperidines, and methods of use thereof | SEPRACOR INC. | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177607-A1 | 4,4-Disubstitued piperidines, and methods of use thereof | HTR2C, HTR5A, OPRL1 | SLC6A4 10/4885SLC6A3 4/4885SLC6A2 14/4885 |
| US-20070225331-A1 | 4,4-Disubstituted piperidines, and methods of use thereof | HTR5A, HTR2C, OPRL1 | SLC6A4 11/4885SLC6A3 5/4885SLC6A2 14/4885 |
| US-20040142974-A1 | 4,4-disubstituted piperidines, and methods of use thereof | HTR5A, HTR2C, OPRL1 | SLC6A4 11/4885SLC6A3 5/4885SLC6A2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.